How to become an angel investor
With our Partner Swiss ICT Investor Club (SICTIC), we organized the first Angel Investor workshop in the Basel Area.
Thomas Dübendorfer and Ralph Mogicato
About 30 interested persons joined this hybrid event held at the coworking space The 5th Floor Muttenz or watched the live stream.
The speakers Dr. Thomas Dübendorfer, President and Co-Founder of the Swiss ICT Investor Club (SICTIC) and Ralph Mogicato, Vice President of Swiss ICT Investor Club (SICTIC), provided an introduction for aspiring angel investors on how to invest in Swiss tech startups successfully. Both speakers could show from their many years of experience how to become a happy angel investor and what an important role smart money plays.
Angel investors share their knowledge
The difference between a traditional investor and an angel investor became evident: angel investors share their skills, work experience, domain knowledge, network to experts and potential customers, in addition to money.
Angel investors typically invest 200’000 to 1.5 million francs per project, depending on the complexity of the deal. It also became clear that it is vital to do a pragmatic and accurate due diligence process identifying people, business and legal risks before investing. Also, some caveats need to be considered when investing in tech startups:
Don’t invest if the entrepreneur does not invest his own money into the startup, don’t invest alone and don’t invest more money than you can afford to lose.
This event is the beginning of a collaboration between SICTIC and Basel Area Business & Innovation, which supports startups through its entrepreneurship program and accelerators like the i4Challenge.
Of the 260 or more companies we have supported and helped to establish in the last four years, a significant number have used business angel type financing.
To join the SICTIC Investor Community, learn more and apply at www.sictic.ch/investors.
Watch the recorded live stream here.
Share this article
You may also be interested in
The Basel-based pharma company BioVersys has received 2.7 million euros in funding alongside two partners. This financing serves to help...Read More
The Basel-based start-up docdok.health has developed an app that aims to increase the safety and efficacy of COVID-19 vaccinations. The...Read More